Plus   Neg

Ardelyx Inc. (ARDX) Has Jumped To A 5-Month High On Phase 3 Study Results

Ardelyx Inc. (ARDX) announced after the bell Wednesday that its Phase 3 study of tenapanor, for irritable bowel syndrome with constipation, achieved statistical significance for the primary endpoint and all secondary endpoints.

Ardelyx gapped open sharply Thursday morning and is now up 2.42 at $7.82 on the highest volume of the year. The stock has jumped to a 5-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT